Cargando…

Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial

Definite cure remains exceptional in myeloma patients even after high-dose chemotherapy (HDCT) with melphalan (Mel) and autologous stem cell transplantation (ASCT). Thus, improving efficacy of HDCT in MM remains an unresolved issue. This randomized phase II trial compared standard 200 mg/m(2) Mel HD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Farag, Sarah, Bacher, Ulrike, Jeker, Barbara, Legros, Myriam, Rhyner, Gaelle, Lüthi, Jean-Marc, Schardt, Julian, Zander, Thilo, Daskalakis, Michael, Mansouri, Behrouz, Manz, Chantal, Pabst, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018972/ https://www.ncbi.nlm.nih.gov/pubmed/35444232 http://dx.doi.org/10.1038/s41409-022-01681-y

Ejemplares similares

Comparison of Melphalan Combined with Treosulfan or Busulfan as High-Dose Chemotherapy before Autologous Stem Cell Transplantation in AML
por: Gurevich, Ekaterina, et al.
Publicado: (2022)

Efficacy and Safety of High-Dose Chemotherapy with Treosulfan and Melphalan in Multiple Myeloma
por: Gillich, Cédric, et al.
Publicado: (2023)

Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation
por: Frankiewicz, Andrzej, et al.
Publicado: (2018)

BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) as Conditioning Regimen Before Autologous Haematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis
por: Wu, Ran, et al.
Publicado: (2023)

Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan.
por: Moscow, J. A., et al.
Publicado: (1993)

BeEAM Conditioning including High-Dose Bendamustine before Autologous Stem Cell Transplantation Is Safe and Effective in Patients with Waldenstrom’s Macroglobulinemia
por: Heini, Alexander D., et al.
Publicado: (2023)

Salvage bortezomib–dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial
por: Gimsing, P, et al.
Publicado: (2015)

Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
por: Lee, Se Ryeon, et al.
Publicado: (2019)

Factors influencing the chemosensitization of melphalan by misonidazole.
por: Randhawa, V. S., et al.
Publicado: (1985)

Gastrointestinal Bleeding Secondary to High-Dose Melphalan Pretreatment in Patients with Multiple Myeloma Was Associated with the Mode of Melphalan Administration
por: Ge, Qunfang, et al.
Publicado: (2022)

The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin's Lymphoma
por: Pangarsa, Eko A., et al.
Publicado: (2021)

Retracted: Gastrointestinal Bleeding Secondary to High-Dose Melphalan Pretreatment in Patients with Multiple Myeloma Was Associated with the Mode of Melphalan Administration
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Conditioning with melphalan 200 mg/m(2) and subsequent ASCT improves progression‐free and overall survival in elderly myeloma patients compared to standard of care
por: Afram, Gabriel, et al.
Publicado: (2022)

The effect of systemic hyperthermia on melphalan pharmacokinetics in mice.
por: Honess, D. J., et al.
Publicado: (1985)

The effect of radiosensitizers on the pharmacokinetics of melphalan and cyclophosphamide in the mouse.
por: Hinchliffe, M., et al.
Publicado: (1983)

Oral Melphalan Therapy in Advanced Malignant Disease
por: Clifford, Peter, et al.
Publicado: (1963)

Nitric oxide enhancement of melphalan-induced cytotoxicity.
por: Cook, J. A., et al.
Publicado: (1997)

Intravitreal and Subconjunctival Melphalan for Retinoblastoma in Transgenic Mice
por: Shah, Nisha V., et al.
Publicado: (2014)

Intravitreal Melphalan Chemotherapy for Vitreous Seeds in Retinoblastoma
por: Yousef, Yacoub A., et al.
Publicado: (2020)

Intravitreal melphalan for persistent retinoblastoma vitreous seeds
por: Redondo-Villanueva, Marie Jeazelle H., et al.
Publicado: (2022)

Toxicity to intravitreal melphalan in a patient with retinoblastoma
por: Solaz-Ruiz, Marta Gema, et al.
Publicado: (2023)

Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Rodriguez, Tulio E., et al.
Publicado: (2016)

Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma
por: Byun, Ja Min, et al.
Publicado: (2018)

Stem Cell Mobilization with Ixazomib and G-CSF in Patients with Multiple Myeloma
por: Bühler, Selina, et al.
Publicado: (2023)

The effects of melphalan and misonidazole on the vasculature of a murine sarcoma.
por: Murray, J. C., et al.
Publicado: (1987)

Response of two mouse tumours to hyperthermia with CCNU or melphalan.
por: Joiner, M. C., et al.
Publicado: (1982)

Repeat administration of high dose melphalan in relapsed myeloma.
por: Mansi, J. L., et al.
Publicado: (1993)

Intravitreal Melphalan for Vitreous Seeds: Initial Experience in China
por: Ji, Xunda, et al.
Publicado: (2016)

Melphalan modifies the bone microenvironment by enhancing osteoclast formation
por: Chai, Ryan C., et al.
Publicado: (2017)

Ocular toxicity of intravitreal melphalan for retinoblastoma in Chinese patients
por: Xue, Kang, et al.
Publicado: (2019)

Comparison of efficacy and toxicity of intravitreal melphalan formulations for retinoblastoma
por: Hsieh, Terry, et al.
Publicado: (2020)

Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes
por: Byrgazov, Konstantin, et al.
Publicado: (2021)

Melphalan intra-arterial chemotherapy for choroidal melanoma chemoreduction
por: Jorge, Rodrigo, et al.
Publicado: (2022)

The Combination of Panobinostat and Melphalan for the Treatment of Patients with Multiple Myeloma
por: Gkotzamanidou, Maria, et al.
Publicado: (2022)

Busulfan plus melphalan versus melphalan alone conditioning regimen after bortezomib based triplet induction chemotherapy for patients with newly diagnosed multiple myeloma
por: Park, Songyi, et al.
Publicado: (2021)

Hematopoietic Stem Cell Mobilization With Plerixafor Is Safe and Effective in Poorly Mobilizing Acute Myeloid Leukemia Patients
por: Shumilov, Evgenyi, et al.
Publicado: (2019)

Potentiation of the anti-tumour effect of melphalan by the vasoactive agent, hydralazine.
por: Stratford, I. J., et al.
Publicado: (1988)

Effect of renal dysfunction in dogs on the disposition and marrow toxicity of melphalan.
por: Alberts, D. S., et al.
Publicado: (1981)

Clonal variation in the sensitivity of a murine mammary carcinoma to melphalan.
por: McMillan, T. J., et al.
Publicado: (1986)

Adriamycin/cyclophosphamide and adriamycin/melphalan in advanced L1210 leukaemia.
por: Tobias, J. S., et al.
Publicado: (1975)

Cannot write session to /tmp/vufind_sessions/sess_egu9hmpp29qpgdov8e1h0ale8b